Latest Earnings Results: Q2 '26
Estimated EPS
$0.02
Reported EPS
---
Surprise
---
Estimated Rev
$91.9M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.10 up 52.38% YoY • Reported revenue of $80.1M up 23.25% YoY • Esperion Therapeutics expects continued operating losses and consistent research and development expenses in 2026, with selling, general and administrative expenses anticipated to increase slightly in 2026.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.00 | -- | -- | N/A |
Q2 '26 | $0.02 | -- | -- | N/A |
Q1 '26 | -$0.04 | -$0.10 | -169.23% | MISSED |
Q4 '25 | $0.24 | $0.22 | -9.59% | MISSED |
Q3 '25 | -$0.08 | -$0.16 | -104.27% | MISSED |